What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.
SILVER SPRING, Md., Sept. 11, 2023 /PRNewswire/ — Today, the U.S. Food and Drug Administration took action approving and authorizing for emergency use updated COVID-19 vaccines formulated to more closely target currently circulating variants and to provide better protection against…
Commenting on the development, Rodeina Challand, VP Scientific affairs said: “This is a critical milestone in the development of a biosimilar candidate for Stelara. Comparative PK studies are considered pivotal for demonstrating biosimilarity between the biosimilar candidate and the reference product”.
Jeffrey Hausfeld MD, MBA, Chief Medical Officer, and Chairman of the Board stated: “Being part of the cadre of physicians that introduced the adoption of generics from branded small molecule drugs in the 1980’s has provided me with a clear perspective of the controversies and trajectory of acceptance of biosimilars in the marketplace by patients, payors and physicians. While all stakeholders work through the debates of the need and benefits of interchangeable switching studies, and large Phase 3 safety and efficacy trials for biosimilar regulatory approvals, BioFactura will continue to focus on the development of high quality and reasonably priced biosimilar products to add value and improved outcomes for patients around the globe.”
On July 10, 2023, BioFactura, Inc. announced that CuraTeQ Biologics Private Limited, a wholly owned subsidiary of Aurobindo Pharma Limited, has entered into an exclusive global license to commercialize BFI-751, BioFactura’s proposed biosimilar to Stelara (Ustekinumab).
About BioFactura, Inc. BioFactura, Inc. (Frederick MD) develops and commercializes high-value biodefense medical countermeasures and biosimilars (i.e., follow-on biologics or generic biopharmaceuticals) using its patented StableFast™ Biomanufacturing Platform, the optimal system for bringing these drugs to market with faster, lower cost, superior-quality manufacture. For over 15 years, BioFactura has been advancing life-saving medicines from the research bench to the patient using its innovative drug development and manufacturing technologies. Current and past programs include biodefense drugs against smallpox and Ebola, novel medicines for cancer, and low-cost/high-quality biosimilars for autoimmune and infectious diseases.
Media Contact
Jeffrey Hausfeld MD, MBA, BioFactura, 301-792-8601, [email protected], www.biofactura.com
SOURCE BioFactura
Notable, sought-after speakers will join top minds from beauty and wellness brands. The speaking lineup includes:
“We are thrilled to host such an impressive group and are overwhelmed by the response we’ve received,” said Sudheer Koneru, Zenoti co-founder and CEO. “Leaders across the industry tell us how excited they are to join in this unique opportunity. We all look forward to meeting, networking, sharing… all to help everyone succeed in this industry we care so much about.”
The event’s theme, “Shape the Next,” celebrates the collaborative energy of Innergize – and the forward-thinking spirit of the people in beauty and wellness. Over three days, leaders and innovators will share expertise on business growth, AI technology, marketing tactics, staff retention and motivation, data-driven strategies, franchising, membership revenue, and other topics.
Innergize will place a special focus on AI, with multiple sessions on the use of AI in today’s salons and spas, and a look at AI innovations coming soon to the industry.
Amid the collaborative learning environment, Innergize shines a light on the industry’s people – from Elizabeth Gilbert’s keynote address on finding and nourishing inner greatness, to the Golden Hands awards ceremony, highlighting the greatest stylists, massage therapists, medspa clinicians, and other providers.
“I can’t think of another event like this,” said Koneru, “in which people can learn from and celebrate others across the entire industry. Not just large, enterprise businesses, and more than just a salon-specific or spa-specific agenda. Everyone attending can benefit – but also contribute to crafting best practices their peers can apply to their own businesses in the months and years to come.”
The headquarters for the inaugural Innergize event is the beautiful Hyatt Regency Seattle, just a mile from the iconic Space Needle. The evening celebration of the industry – and its standout service providers – takes place at the eclectic Museum of Pop Culture (MoPOP).
ABOUT ZENOTI
With the industry’s most complete end-to-end growth platform, Zenoti helps 25,000+ beauty and wellness businesses find their greatness. The choice of top salons, spas, medical spas, and fitness centers, Zenoti helps ambitious brands grow their business, elevate the guest experience, engage and retain their talented staff, and work more efficiently than ever.
Owners, managers, and staff use Zenoti to seamlessly run every aspect of their business, online and in-person. Zenoti provides a single solution that includes online appointment bookings, POS, CRM, employee management and engagement, inventory management, built-in marketing programs, and more. For more information, see zenoti.com.
Media Contact
Norm Schrager, Zenoti, 978.771.9976, [email protected], Innergize.me
SOURCE Zenoti
Dr. Thunnissen and colleagues conducted a case-control study involving resected adenocarcinomas measuring up to 3 cm (n=70), the research evaluated the potential of a modified classification system. The modified classification factored in iatrogenic collapsed adenocarcinoma in situ, identified through elastin and cytokeratin 7 staining. Pathologists initially assessed the cases according to the WHO criteria and then underwent a tutorial, after which they scored the cases based on the modified classification. A heatmap analysis was conducted to identify areas commonly or less frequently identified as invasive.
The study drew participation from 42 pathologists across 13 countries who scored the cases in three rounds. The kappa values for the three rounds were 0.27, 0.45, and 0.62, respectively. These results indicated that the standard WHO criteria for determining invasion faced challenges in achieving consistent and reproducible results.
However, the modified classification exhibited notably higher reproducibility. Pathologists displayed a more significant increase in competence, reflected by a higher kappa score, both when evaluated blindly (0.45) and with guidance (0.62). The outcomes suggested that the revised classification overcomes the limitations of the WHO criteria, thereby addressing concerns about inconsistent assessments.
Importantly, the research revealed that cases scored with “no-invasion” consensus in the second and third rounds achieved a 100% recurrence-free survival (RFS) rate. The diagnosis of adenocarcinoma in situ after resection with the modified classification implies that the patient is cured. In contrast, with the diagnosis of invasive adenocarcinoma in these cases based on the WHO classification, the patient has to bear the anxiety of a chance of recurrence.
Further bolstering the modified classification, biomarker analyses associated with invasion and poor outcomes were conducted. These analyses unveiled intriguing correlations, including a low proliferation rate in adenocarcinoma in situ compared to invasive adenocarcinomas and the presence of TP53 mutations in invasive adenocarcinomas, underscoring their role as late-stage events.
“Our findings suggest that the modified adenocarcinoma classification significantly enhances reproducibility and aligns better with the clinical reality. These results open new avenues for refining our understanding of these cancers and improving patient care,” Dr. Thunnissen reported.
“These findings could enable a more confident diagnosis and treatment decisions for patients with pulmonary adenocarcinomas,” he said.
About the IASLC:
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association’s membership includes more than 8,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit http://www.iaslc.org for more information.
About the WCLC:
The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 7,000 researchers, physicians, and specialists from more than 100 countries. The goal is to increase awareness, collaboration, and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit https://wclc2023.iaslc.org.
Media Contact
Chris Martin, IASLC, 6306702745, [email protected], https://wclc2023.iaslc.org.
SOURCE IASLC
Mesothelioma, a rare and aggressive cancer primarily linked to asbestos exposure, has prompted exploration into various treatment options, including surgical procedures like pleurectomy decortication. However, despite its common use, the effectiveness of this intervention has never been evaluated in a randomized trial.
The trial, which enrolled 335 participants, randomly assigned 169 patients with resectable mesothelioma to extended pleurectomy decortication and 166 patients to chemotherapy (platinum and pemetrexed) or chemotherapy alone.
The researchers followed patients for a median 22.4 months.
Patients randomized to surgery and chemotherapy exhibited a median survival of 19.3 months, while those randomized to chemotherapy alone demonstrated a median survival of 24.8 months. However, the hazards for death were non-proportional, prompting the presentation of primary outcomes in two timeframes: randomization to 42 months and beyond 42 months. The analysis indicated a 28% increase in the risk of death in the surgery group within the first 42 months, while no significant difference in survival emerged after 42 months, Lim reported.
Moreover, the research unveiled significant disparities in progression-free survival and adverse events between the two groups. The surgery group experienced a 3.6-fold higher incidence of serious adverse events (CTCAE grade 3 and above), and Dr. Lim reported that patients who underwent surgery reported poorer quality of life and well-being on various EORTC health-related quality of life scales, particularly in global health, physical functioning, social functioning, and role functioning. The surgery group also exhibited worse positive symptom scores, including pain, dyspnea, insomnia, loss of appetite, and financial difficulties.
Prof. Lim concluded that extended pleurectomy decortication should not be offered to patients with pleural mesothelioma and classifying this disease as “unresectable” from the outset would increase access to more effective systemic treatments to improve survival for patients with early-stage disease.
About the IASLC:
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association’s membership includes more than 8,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit http://www.iaslc.org for more information.
About the WCLC:
The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 7,000 researchers, physicians, and specialists from more than 100 countries. The goal is to increase awareness, collaboration, and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit https://wclc2023.iaslc.org.
Media Contact
Chris Martin, IASLC, 6306702745, [email protected], https://wclc2023.iaslc.org.
SOURCE IASLC
The study enrolled 557 patients and randomized them 1:1 into two treatment arms: osimertinib plus chemotherapy or osimertinib monotherapy. The combination arm involved a regimen of osimertinib (80 mg daily) alongside pemetrexed and either cisplatin or carboplatin.
“Results from the study demonstrated a remarkable improvement in progression-free survival (PFS) with the osimertinib plus chemotherapy approach, showcasing a statistically significant reduction in disease progression risk compared to osimertinib monotherapy,” Dr. Jänne said.
The data showed a compelling hazard ratio of 0.62 (95 percent CI 0.49, 0.79; p less than 0.0001) for progression-free survival, signifying an 8.8-month enhancement in median progression-free survival. Moreover, the objective response rate per investigator was notably higher in the combination arm at 83%, compared to 76% in the osimertinib monotherapy group. Safety analyses revealed that the combination therapy was generally well-tolerated, with manageable adverse events.
“These findings mark a significant advancement in the management of advanced EGFR-mutated NSCLC,” Dr. Jänne reported. “The FLAURA2 study supports osimertinib combined with platinum-pemetrexed chemotherapy as a new and promising first-line treatment option, poised to make a profound impact on patient outcomes in this challenging disease setting.”
About IASLC
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association’s membership includes more than 8,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit http://www.iaslc.org for more information.
About the WCLC:
The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 7,000 researchers, physicians, and specialists from more than 100 countries. The goal is to increase awareness, collaboration, and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit https://wclc2023.iaslc.org.
Media Contact
Chris Martin, IASLC, 6306702745, [email protected], https://wclc2023.iaslc.org.
SOURCE IASLC
Current State of Cancer Immunotherapy Theranostics
Cancer immunotherapy theranostics are the predictive biomarkers of immunotherapy response. However, current tissue- or blood-based assays do not encompass all potential patient responses and there is a need for continued enhancement in predictive capabilities. Hear about the clinical outcomes and data related to clinically utilized biomarkers for cancer immunotherapy such PD-L1, TMB, MSI and MMR in selected cancer types, along with insights into Quibim’s experiences with cancer immunotherapy imaging classifiers.
Visualizing Patient Response with CD8+ T cells in Cancer
Evidence suggests CD8+ cells in lymph nodes or other lymphoid organs could play an important role in the tumor immunity cycle and response to immunotherapy. Learn about the advantages of full body imaging of cancer patients focused on CD8+ cell status (CD8 ImmunoPET), particularly during cancer immunotherapy, revealing full-body CD8+ cell distributions in multiple lesions, lymph nodes and other lymphoid organs.
Radiomics and Artificial Intelligence
Hear about the integration of AI techniques in radiomics analysis for cancer immunotherapy response prediction. When coupled with AI, a machine/deep learning algorithm can learn to adjust the importance of radiomic features — which include tissue and lesion characteristics such as heterogeneity and shape — or pattern and their interactions, to combine them into a predictive signature. AI-derived clinical decision support algorithms can assist clinicians to achieve earlier and better identification of responders, non-responders and those likely to develop adverse events.
Register for the live webinar taking place on Wednesday, September 27, 2023, at 2pm EDT (11am PDT) that will feature speakers Michael Ferris, PhD, Associate Director of Operations, ImaginAb Europe Ltd.; Glen J. Weiss, MD, MBA, Chief Medical Officer (CMO), Quibim; and Ana Jimenez-Pastor, VP of Artificial Intelligence (AI), Quibim.
For more information, or to register for this event, visit Cancer Immunotherapy: Exploring Imaging as a Catalyst to Immune Response Prediction.
Quibim is transforming precision medicine by delving beyond what the human eye can see. The company employs AI-powered imaging tools derived from years of intensive research to assist doctors in diagnosis and anticipating patient progression. Quibim’s solutions transform imaging data into actionable predictions, enhancing patient outcomes and driving medical imaging innovation. Now internationally expanded, Quibim is excited to introduce their new line of products focused on predictive imaging biomarker panels, ensuring continuous advancement in life sciences and provider solutions.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Media Contact
Ayesha Rashid, Xtalks, +1 (416) 977-6555 x272, [email protected]
SOURCE Xtalks
After spending over 20 years in the corporate world, Scott decided he needed a revamp and reboot. He discovered Caring Transitions through his sister, who lives in Arizona. Couple that with caring for an ageing parent himself over the last few months, Scott confessed that the services and support that Caring Transitions offered seemed like a natural fit and met his goal of helping others in any new venture he undertook.
“I understand what families go through and the stress it can put on them when you’re trying to juggle your own life, and also have to deal with an emotional and uncertain situation,” Scott said. “Being able to help a family through a challenging time is really valuable, especially because I see myself eventually needing that with my own parent when there needs to be a different living arrangement.”
Caring Transitions of East Stroudsburg will serve East Stroudsburg, Bushkill, Cresco, Dingman’s Ferry, Hawley, Milford, The Poconos, Stroudsburg, Tobyhanna and surrounding areas. Scott is looking forward to helping minimize stress for families during what can be a difficult time in a loved one’s life.
“Going through a transition like moving for seniors can be challenging and fraught with emotion,” Scott said. “Having someone to lighten the load and take charge of details can be extremely beneficial.”
“Scott is certainly somebody that gets it,” said Ray Fabik, President of Caring Transitions. “He empathizes with clients because he himself has an aging parent. It’s clear he cares about his community and his team will be a valuable asset to anyone in the Stroudsburg area who needs help downsizing or re-focusing their living situation.”
To learn more about Caring Transitions, visit http://www.CaringTransitions.com.
For more about franchising opportunities with Caring Transitions, visit https://www.caringtransitionsfranchise.com/.
About Caring Transitions
Caring Transitions, founded in 2006, is the most trusted and experienced national franchise specializing in senior relocation and transition services. With more than 280 locations throughout the United States, all owned and operated by Certified Relocation and Transition Specialists, Caring Transitions provides clients with supportive moves, auctions, rightsizing, and transitions. This includes expert advice plus a well-executed transition plan beginning with the initial sorting of personal belongings through packing, unpacking, resettling, and selling of items to the final clearing and cleaning of the property. For more information, visit http://www.caringtransitions.com or visit us on Facebook.
Media Contact
Mike Toper, 919 Marketing.com, (919) 813-6511, [email protected], 919marketing.com
SOURCE Caring Transitions
The panel will present case studies to illustrate the power of empathy in recruitment, share solutions to reduce common challenges, and respond to your live questions and feedback as they discuss the five “Must Haves”:
“Although it enables efficiency and scale, technology cannot stand alone in addressing the challenges posed by global patient recruitment and enrollment for clinical trials,” Walz said. “The key is to bring technology and human expertise together to overcome these barriers, improve recruitment, and ensure successful enrollment – for sponsors, sites, and most importantly the patients and families we ultimately serve”
Register to join the virtual panel. After the webinar concludes, a recording will be provided to everyone who registered for on-demand viewing.
To request a demonstration of Trialbee Honey, visit https://www.trialbee.com.
About Trialbee
Trialbee is revolutionizing the patient recruitment ecosystem with technology, people, and passion. Our vendor-agnostic Honey Platform™ provides sponsors and CROs unprecedented transparency, real-time patient tracking, and visual ROI reporting across all recruitment partners, sources, and channels in a centralized funnel. Trialbee also offers precision recruitment that features data-driven modeling, hyper-targeted digital outreach, and medical secondary screening. Together with our team’s Omnichannel network, hands-on consultative approach, and global expertise, Trialbee will help you take control of your global patient recruitment. For more information, visit https://www.trialbee.com/.
Media Contact
Kristopher Sarajian, Trialbee, 1 610.228.2112 , [email protected], www.trialbee.com
SOURCE Trialbee
“We are thrilled to celebrate the opening of our 10th clinic in Central Surrey. This expansion embodies our core belief that every individual has the potential to thrive and contribute to the vibrant tapestry of life,” shared Chelsea Ganam, President of Monarch House. “Belonging is at the heart of what we do, and this clinic will be a nurturing space where families can feel safe, appreciated and receive quality support.”
This expansion comes on the heels of recent successful clinic openings, including new locations in Toronto and Markham, Ontario as part of Monarch House’s ongoing growth strategy.
For more information about the new Central Surrey clinic and the services offered, interested families are invited to contact (778) 262-1100 or visit www.monarchhouse.ca
About Monarch House
Founded in 2008, with clinics located in British Columbia, Alberta, and Ontario, Monarch House puts outcomes for children and families at the forefront of everything it does—by improving access and coordinating services for individuals with autism spectrum disorder, developmental delays, and changing behavioural needs throughout their lifespan. Monarch House’s Board Certified Behaviour Analysts, speech-language pathologists, occupational therapists, psychologists and pediatrician work collaboratively and individually as required to deliver evidence-based services. Monarch House is committed to continuous learning and conducts research to advance understanding and provide the most effective services possible. www.monarchhouse.ca
Media Contact
Chelsea Ganam, Monarch House, 1 7782299344, [email protected], www.monarchhouse.ca
SOURCE Monarch House
